RTP Gene Tech Firm Lands Deal Worth Up to $90M for 8 Nervous System Therapies

StrideBio, a life science startup focused on gene-editing technology, has a deal in place with a Massachusetts drug firm that could be worth nearly $90M plus royalties in years to come for rights to as many as eight potential gene-based therapies.

Any developed drug would focus on the central nervous system and neuromuscular “targets,” StrideBio and its partner Sarepta Therapeutics announced.

StrideBio, which launched in 2015, is focused on engineered viral vectors, or AAV, for gene therapy. The technology at StrideBio is based on the work of Dr. Aravind Asokan at UNC-Chapel Hill and Dr. Mavis Agbandje-McKenna at the University of Florida.

Learn more about RTP Gene Tech Firm Lands Deal Worth Up to $90M for 8 Nervous System Therapies.